Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy ...

A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with ...

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer ...

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical ...